Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07922070
PHASE1

A Bioequivalence Study of Olanzapine Samidofen Tablets in Healthy Subjects Under Fasting Conditions.

Sponsor: The Affiliated Hospital of Qingdao University

View on ClinicalTrials.gov

Summary

To investigate the pharmacokinetics and evaluate the bioequivalence of a single oral dose of the test preparation Olanzapine Samidofen Tablets versus the reference preparation Olanzapine Samidofen Tablets (LYBALVI®) in healthy adult subjects under fasting conditions.

Official title: A Bioequivalence Study of the Test Preparation Olanzapine Samidofen Tablets Versus the Reference Preparation Olanzapine Samidofen Tablets (LYBALVI®) in Healthy Subjects Under Fasting Conditions.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2025-10-23

Completion Date

2025-11-15

Last Updated

2026-11-06

Healthy Volunteers

Yes

Interventions

DRUG

Test Olanzapine Samidofen Tablets

The Olanzapine Samidofen Tablets, with a specification of 5 mg olanzapine and 10 mg samidofen per tablet (abbreviated as 5mg/10mg; the actual product information shall prevail), were manufactured and supplied by Qilu Pharmaceutical Co., Ltd.

DRUG

reference (LYBALVI®) Olanzapine Samidofen Tablets

Olanzapine Samidofen Tablets (Brand Name: LYBALVI®), with a specification of 5 mg olanzapine and 10 mg samidofen per tablet (abbreviated as 5mg/10mg; the actual product information shall prevail), is marketed by Alkermes, Inc., and was supplied by Qilu Pharmaceutical Co., Ltd.

Locations (1)

The Affiliated Hospital of Qingdao University Phase I Clinical Research Center

Qingdao, Shandong, China